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Context: Subclinical hypothyroidism is not a rare condition, but theuseof thyroidhormone to treat
subclinical hypothyroidism is an issue of debate.
Objective: This studywas undertaken to investigate the impact of thyroid hormone therapy on the
changes in estimated glomerular filtration rate (eGFR) in subclinical hypothyroidism patients with
stage 2–4 chronic kidney disease.
Patients: A total of 309 patients were included in the final analysis.
Main Outcome Measure: The changes in eGFR over time were compared between patients with
and without thyroid hormone replacement therapy using a linear mixed model. Kaplan-Meier
curveswere constructed todetermine theeffectof thyroidhormoneon renaloutcome, a reduction
of eGFR by 50%, or end-stage renal disease. The independent prognostic value of subclinical
hypothyroidism treatment for renal outcome was ascertained by multivariate Cox regression
analysis.
Results: Among the 309 patients, 180 (58.3%) took thyroid hormone (treatment group), whereas
129 (41.7%) did not (nontreatment group). During the mean follow-up duration of 34.8  24.3
months, the overall rate of decline in eGFR was significantly greater in the nontreatment group
compared to the treatment group (5.93  1.65 vs. 2.11  1.12 ml/min/yr/1.73 m2; P  0.04).
Moreover, a linearmixedmodel revealed that therewasa significantdifference in the ratesofeGFR
declineover timebetween the twogroups (P0.01). Kaplan-Meier analysis also showed that renal
event-free survival was significantly lower in the nontreatment group (P  0.01). In multivariate
Cox regression analysis, thyroid hormone replacement therapy was found to be an independent
predictor of renal outcome (hazard ratio, 0.28; 95% CI, 0.12–0.68; P  0.01).
Conclusion: Thyroid hormone therapy not only preserved renal function better, but was also an
independent predictor of renal outcome in chronic kidney disease patients with subclinical
hypothyroidism. (J Clin Endocrinol Metab 97: 2732–2740, 2012)
Because thyroid hormone has numerous effects on thekidney, heart, and vascular system, thyroid dysfunc-
tion can cause significant changes in renal and cardiovas-
cular functions (1–3). In particular, hypothyroidism is
known to be associated with reduced renal plasma flow
(RPF) and low glomerular filtration rate (GFR). In addi-
tion, decreased renal sodium reabsorption and decreased
renal ability to dilute urine, resulting in hyponatremia, are
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frequently observed in patients with hypothyroidism (2,
3). Moreover, the number of risk factors for coronary
heart disease, including hypertension, dyslipidemia, and
hyperhomocysteinemia, are increased in hypothyroidism
patients, which is in part associated with more coronary
heart disease events and higher cardiovascular mortality
(4, 5).
Subclinical hypothyroidism, defined as elevated serum
TSH but normal free T4 (fT4) level, is not a rare disease.
The prevalence of subclinical hypothyroidism has been
reported to be about 4 to 10% in the adult population and
to increase with age, especially in females after the age of
45 yr (6). In addition, subclinical hypothyroidism is more
common in women than men, in whites than blacks, and
in areas of high iodine intake (7, 8). Factors such as pre-
vious history of hyperthyroidism or head and neck cancer
treated with external beam radiation, a family history of
thyroid disease, and ingestion of amiodarone, an iodine-
containing drug, also raise the likelihood of subclinical
hypothyroidism (6). Moreover, previous studies have
shown a close interrelationship between chronic kidney
disease (CKD) and subclinical hypothyroidism (9–11).
The prevalence of CKDwas high in patients with overt as
well as subclinical hypothyroidism (12). The risk of ne-
phropathy was increased in type 2 diabetic patients with
subclinical hypothyroidism (13). Conversely, subclinical
hypothyroidismwas frequently observed in CKDpatients
(14). Cardiac abnormalities, such as impaired left ventric-
ular diastolic functionat rest and systolic dysfunctionwith
exertion, were also associated with subclinical hypothy-
roidism (15). Furthermore, even aminor elevation of TSH
was surmised to play a role in the development of athero-
sclerosis and tohave adverse effects on cardiovascular per-
formance in the general population (8, 16).
Replacement of thyroid hormone is fundamental in the
treatment of hypothyroidism patients. It not only relieves
the symptoms of hypothyroidism, but also alleviates the
deleterious effects of hypothyroidism on the kidney and
heart (10, 17–20). Normalization of RPF and GFR were
demonstrated in primary hypothyroidism patients treated
with thyroid hormone (21, 22). In addition, restoration of
euthyroidism improved GFR in CKD patients with overt
hypothyroidism (10, 18, 19). Cardiovascular complica-
tions of overt hypothyroidismwere also abrogated by thy-
roid hormone replacement (20). However, between sev-
eral existing guidelines, there has been a lack of consensus
on whether to treat subclinical hypothyroidism patients
with thyroid hormone or not. Some previous studies have
shown that L-thyroxine improves cardiac function and
lowers the low-density lipoprotein (LDL)-cholesterol level
in patients with subclinical hypothyroidism (23–26),
whereas other studies failed to demonstrate the beneficial
effects of L-thyroxine supplement in these patients (27).
On the other hand, the impact of thyroid hormone re-
placement has not been extensively studied in CKD pa-
tients with subclinical hypothyroidism. In particular, it
has not been evaluated whether the restoration of eu-
thyroidism is beneficial in terms of preserving renal
function in these patients. In this study, therefore, we
explored the effect of thyroid hormone replacement for
subclinical hypothyroidism on the changes in GFR in
adult CKD patients.
Subjects and Methods
Ethics statement
This studywas carriedout in accordancewith theDeclaration
of Helsinki and approved by the Institutional Review Board
(IRB) of Yonsei University Health System Clinical Trial Center.
All patients participating in the current study were aware of this
investigation. However, because this study was a retrospective
medical record-based study and the study subjects were de-iden-
tified, the IRB waived the need for written consent from the
patients.
Study subjects
For this study, we initially recruited 570 patients who had
stage 2–4 CKD andwere biochemically diagnosed with subclin-
ical hypothyroidism at Yonsei University Health System, Seoul,
Korea, between January 2005 and December 2010. Of these
patients, 226were excluded for the following reasons: age below
18 yr (n  27) or above 75 yr (n  20), heavy proteinuria in-
cluding nephrotic syndrome (n 31), terminal malignancy (n
28), pregnancy (n  5), already on thyroid hormone or other
hormone treatment (n66), and follow-upduration less than12
months (n 49).We also excluded 35 patients whose TSH level
was higher than 10 IU/ml. Thus, a total of 309 patients were
included in the final analysis.
Data collection
Demographic and clinical data at the time of diagnosis of
subclinical hypothyroidism, including age, gender, comorbidi-
ties such as cardiovascular disease, and blood pressure, were
recorded. Cardiovascular disease was defined as a history of
coronary, cerebrovascular, or peripheral vascular disease; cor-
onary disease was defined as a history of angioplasty, coronary
artery bypass grafts, myocardial infarction, or angina; cerebro-
vascular disease was defined as a previous history of transient
ischemic attack, stroke, or carotid endarterectomy; whereas pe-
ripheral vascular diseasewas defined as a history of claudication,
ischemic limb loss and/or ulceration, or peripheral revascular-
ization procedure. The results of the following concurrent lab-
oratory tests were also collected: serum calcium, phosphate,
albumin, total cholesterol, and triglyceride levels. Estimated
GFR (eGFR) (ml/min/1.73 m2) was calculated using the four-
variableModification of Diet in Renal Disease study (MDRD)
equation (28): eGFR (ml/min/1.73 m2)  175  (serum creat-
inine)1.154  age0.203  0.742 (if the subject is female) or 
1.212 (if the subject is black). In addition, the stages ofCKDwere
defined according to the AmericanNational Kidney Foundation
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(29): stage 1, eGFR of 90 ml/min/1.73 m2 or greater; stage 2,
eGFR 60–89 ml/min/1.73 m2; stage 3, eGFR 30–59 ml/min/
1.73 m2; stage 4, 15–29 ml/min/1.73 m2; and stage 5, eGFR less
than 15 ml/min/1.73 m2 or dialysis.
Thyroid function test and definition
In all patients, serum T3, fT4, TSH, and antithyroid per-
oxidase antibody (anti-TPO) concentrations were measured.
Serum T3, fT4, and TSH levels were determined by chemilu-
minescence microparticle immunoassay on the Architect-
i2000SR analyzer (Abbott Laboratories, Abbott Park, IL) and
anti-TPO concentration by chemiluminescence assay on a
Roche Cobas E601 analyzer (Hitachi, Hitachinaka, Japan).
The diagnosis of subclinical hypothyroidism was solely based
upon the results of a thyroid function test and was defined as
normal serum fT4 but elevated TSH levels, irrespective of
clinical symptoms of hypothyroidism. Because there was a
possibility of transient elevation of serum TSH concentration,
the measurement of serum TSH level was repeated within 3
months to confirm the diagnosis. The reference ranges of T3,
fT4, and TSH were 0.58–1.59 ng/ml, 0.70–1.48 ng/dl, and
0.35–4.94 IU/ml, respectively.
Treatment of subclinical hypothyroidism
Because thiswas a retrospective clinical study, replacement of
thyroid hormonewas not randomly performed.We surmise that
patients with dyslipidemia, high titers of anti-TPO, and nonspe-
cific symptoms of hypothyroidism, such as fatigue, constipation,
and depression, were prone to receiving thyroid hormone
treatment.
The treated patients were initially administered L-thyroxine
with the lowest dose necessary to normalize serum TSH level,
usually 25 g/d. After the start of thyroid hormone supplement,
serum TSH concentration was remeasured at 5 or 6 wk in most
patients. If the level of TSH remained above the normal reference
range, the dose of L-thyroxinewas increased by 25g/d until the
patient’s serum TSH concentration was reduced to the normal
reference range. The dose of L-thyroxine was adjusted every 3
months according to the follow-up level of TSH.
Statistical analysis
Statistical analysis was performed using SAS software (ver-
sion 9.1.3; SAS Institute Inc., Cary, NC). Continuous variables
were expressed asmean SD and categorical variables as a num-
ber (percentage). To compare differences between the two
groups, Student’s t test or the 2 test was used. The slope of the
decline in renal function over time was calculated by linear re-
gression analysis of serial eGFR for each patient; the slope was
expressed as the regression coefficient (ml/min/yr/1.73 m2). The
changes in eGFRover timewere comparedbetweenpatientswith
andwithout thyroidhormone replacement therapyusing a linear
mixed model. In our implementation of the mixed model, the
intercept and the regression coefficient for the follow-up time
were treated as random effects such that each subject had a
unique intercept and regression coefficient. Cumulative survival
curveswere generatedby theKaplan-Meiermethod todetermine
the effect of thyroid hormone on renal outcome, 50% reduction
of eGFR, or end-stage renal disease (ESRD), and between-group
survivalwas comparedby a log-rank test. The independent prog-
nostic value of subclinical hypothyroidism treatment on renal
outcomewas ascertained bymultivariate Cox proportional haz-
ards regression analysis, which included all covariates with a P
value less than 0.1 on univariate analysis. In addition, Pearson’s
correlation analysiswas performed to elucidate the relationships
between eGFR and TSH level. A P value less than 0.05 was
considered statistically significant.
Results
Baseline characteristics of patients
The baseline demographic, clinical, and biochemical
data of CKD patients with subclinical hypothyroidism
are shown in Table 1. The mean age was 62.2 12.5 yr,
and 173 patients (56.0%) were male. Among the 309
patients, 180 (58.3%) took thyroid hormone, whereas
129 (41.7%) did not. The proportion of diabetes mel-
litus (DM) patients (34.4 vs. 39.5%; P  0.36) and the
serum creatinine concentration tended to be lower
(1.3  0.5 vs. 1.4  0.6 mg/dl; P  0.54) in treated
subclinical hypothyroidism patients with CKD, but the
difference between them and the nontreated patients
did not reach statistical significance. Serum cholesterol
(180.0  39.2 vs. 161.3  48.0 mg/dl; P  0.01) and
triglyceride levels (162.7 121.0 vs. 125.6 63.3 mg/
dl; P  0.01) were significantly higher in patients with
thyroid hormone treatment compared with nontreated
patients. The measurement of anti-TPO concentration
was performed in 140 patients—81 in the treatment
group and 59 in the nontreatment group. Among these
140 patients, high titers of anti-TPO (60 IU/ml) were
demonstrated in 26 patients, all of whom were in the
treatment group (32.1%). In contrast, the mean age, the
proportion of patients with previous history of cardio-
vascular disease, systolic and diastolic blood pressure,
and serum albumin, calcium, phosphate, T3, fT4, and
TSH concentrations were comparable between the two
groups (Table 1). Meanwhile, Pearson’s correlation
analysis revealed that there was a significant inverse
correlation between eGFR and TSH levels (r  0.31;
P 0.01) and a significant positive association between
eGFRand serumT3 concentrations (r 0.27;P 0.01).
Serum TSH levels and blood pressure during
follow-up
Serum TSH levels and blood pressure at various time
points during the follow-up period are listed in Table 2.
Serum TSH concentrations in the treatment group were
significantly decreased to the normal range at 3 months
(P 0.01) and were maintained within the normal range
during the follow-up period, whereas there was no signif-
icant change in serum TSH levels in the nontreatment
group, resulting in significant difference in serum TSH
values between the two groups (P 0.01). In contrast, the
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bloodpressures in the twogroupswere comparableduring
the follow-up period.
Comparison of renal function over time in patients
with and without thyroid hormone replacement
therapy
The results of eGFR were available for at least four time
points within a 6-month interval in all patients. As shown in
Fig.1andTable3,patients in thenontreatmentgrouptended
tohave lowerbaselineeGFRcomparedwithtreatedpatients,
although the difference was not significant. At 12 months,
however, eGFR become significantly lower in patients who
did not receive thyroid hormone therapy (P 0.04). In ad-
dition, the overall rate of decline in eGFR was significantly
greater in the nontreatment group comparedwith that in the
treatment group (5.93  1.65 vs. 2.11  1.12 ml/min/
yr/1.73 m2; P 0.04). Moreover, a linear mixed model re-
vealed that there was a significant difference in the rate of
eGFR decline over time between patients with and without
thyroid hormone replacement therapy [coefficient (0.18,
0.01); P 0.01].
Renal outcome in patients with and without
thyroid hormone replacement therapy
During the mean follow-up duration of 34.8  24.3
months, a 50%decrease in eGFRoccurredmore often in the
nontreatmentgroup(27patients;20.9%)comparedwiththe
treatment group (15 patients; 8.3%), resulting in rates of
7.96 and 2.75 per 100 patient-years, respectively (P  0.01).
The incidenceofESRDwasalso significantlyhigher in thenon-
treatment group relative to the treatment group (2.36 vs. 0.37
per100patients-years;P0.01).Therelativeriskreductionfor
halving the eGFR and achieving ESRD by thyroid hormone
replacement therapy was 64% [95% confidence interval (CI),
0.19–0.67; P  0.001] and 85% (95% CI, 0.03–0.71; P 
0.006), respectively (Table 4).Kaplan-Meier analysis also indi-
catedthatrenalevent-freesurvivalwassignificantlylowerinthe
nontreatment group (P 0.01) (Fig. 2).
TABLE 1. Baseline demographic, clinical, and biochemical characteristics of the subjects
Characteristic Treated patientsa Nontreated patientsb P value
n 180 129
Age (yr) 61.6  12.4 63.7  13.5 0.14
Male, n (%) 102 (56.7) 71 (55.0) 0.78
Body weight (kg) 63.7  11.1 62.6  12.4 0.44
DM, n (%) 62 (34.4) 51 (39.5) 0.36
Hypertension, n (%) 110 (61.1) 79 (61.2) 0.98
Cardiovascular disease, n (%) 27 (15.0) 25 (19.4) 0.31
Systolic blood pressure (mm Hg) 126.3  16.7 123.4  19.2 0.26
Diastolic blood pressure (mm Hg) 74.4  11.4 71.8  12.5 0.12
Follow-up duration (months) 32.0  25.1 36.7  23.5 0.91
T3 (ng/ml) 1.07  0.28 1.04  0.29 0.39
fT4 (ng/dl) 1.12  0.56 1.09  0.25 0.72
TSH (IU/ml) 6.83  1.46 6.73  1.48 0.68
Anti-TPO  60 IU/ml, n (%) 26/81 (32.1) 0/59 (0)
Serum creatinine (mg/dl) 1.32  0.50 1.36  0.59 0.54
eGFR (ml/min/1.73 m2) 57.8  17.0 56.1  19.0 0.43
CKD stage, n (%)c 0.31
Stage 2 85 (47.0) 53 (41.1)
Stage 3 82 (45.8) 64 (49.6)
Stage 4 13 (7.2) 12 (9.3)
Serum albumin (g/dl) 4.26  0.57 4.16  0.76 0.18
Serum calcium (mg/dl) 9.14  0.65 9.08  0.65 0.50
Serum phosphate (mg/dl) 3.64  0.61 3.75  0.65 0.14
Serum cholesterol (mg/dl) 180.0  39.2 161.3  48.0 0.01
Serum triglyceride (mg/dl) 162.7  121.0 125.6  63.3 0.01
Medication use, n (%)
ACEI or ARB 73 (40.6) 62 (48.1) 0.19
Calcium channel blockers 52 (36.1) 44 (39.6) 0.33
-blockers 46 (25.6) 29 (22.5) 0.53
Diuretics 62 (34.4) 48 (37.2) 0.61
Other antihypertensive drugs 13 (7.2) 12 (9.3) 0.51
Statins 53 (29.4) 34 (26.4) 0.55
Values are expressed as mean  SD or number (percentage). eGFR is calculated by MDRD-4 equation. ACEI, Angiotensin-converting enzyme
inhibitor; ARB, angiotensin II receptor blocker.
a Patients who were treated with thyroid hormone for subclinical hypothyroidism.
b Patients who were not treated with thyroid hormone for subclinical hypothyroidism.
c Stage 2, eGFR 60–89 ml/min/1.73 m2; stage 3, eGFR 30–59 ml/min/1.73 m2; stage 4, 15–29 ml/min/1.73 m2.
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Independent predictive value of thyroid hormone
replacement therapy on renal outcome
UnivariateCox regression analysis revealed an increase
in the risk of halving eGFR and ESRD with DM [hazard
ratio (HR), 2.94; 95% CI, 1.58–5.45; P  0.01]. In ad-
dition, male gender (HR, 0.40; 95% CI, 0.21–0.40; P 
0.01) and thyroid hormone therapy (HR, 0.36; 95% CI,
0.19–0.67; P 0.01) were found to be associated with a
lower risk of renal event. The impact of thyroid hormone
replacement therapy on renal outcome remained signifi-
cant even after adjustment for age, sex, DM, eGFR, and
serum cholesterol and triglyceride concentrations (HR,
0.28; 95% CI, 0.12–0.68; P  0.01) (Table 5).
Discussion
Although some previous studies have demonstrated that
restoration of euthyroidism exerts beneficial effects on
FIG. 1. Changes in eGFR over time in subclinical hypothyroidism CKD
patients with (solid line) and without (dotted line) thyroid hormone
replacement therapy. Data are presented as means and SD values.
TABLE 3. Comparison of changes in eGFR over time
in patients with and without thyroid hormone
replacement therapy
Treated
patientsa
Nontreated
patientsb
P
value
n 180 129
eGFR (ml/min/1.73 m2)
At baseline 57.8  17.0 56.1  19.0 0.43
At 6 months 57.8  19.3 52.8  19.6 0.21
At 12 months 57.6  17.0 50.3  25.4 0.04
At 18 months 56.5  18.5 47.7  23.1 0.01
At 24 months 54.4  18.8 45.8  20.1 0.01
At 30 months 55.8  18.9 41.9  21.5 0.01
At 36 months 57.8  19.3 38.9  16.1 0.01
The slope of decline
in eGFR (ml/min/yr/
1.73 m2)
2.11  1.12 5.93  1.65 0.04
Values are expressed as mean  SD. eGFR is calculated by the MDRD-4
equation.
a Patients who were treated with thyroid hormone for subclinical
hypothyroidism.
b Patients who were not treated with thyroid hormone for subclinical
hypothyroidism.
TABLE 2. Comparison of changes in TSH levels and blood pressure over time in patients with and without thyroid
hormone replacement therapy
TSH levels Blood pressure (mm Hg)
Treated patientsa Nontreated patientsb Treated patientsa Nontreated patientsb
n 180 129 180 129
Baseline 6.83  1.46 6.73  1.48 SBP 126.3  16.7 123.4  19.2
DBP 74.4  11.4 71.8  12.5
6 months 1.94  1.38#* 6.92  1.03 SBP 128.8  17.6 126.7  19.9
DBP 76.9  11.1 74.8  12.9
12 months 1.80  1.25#* 7.53  1.13 SBP 134.6  17.6 132.8  19.2
DBP 78.2  11.3 80.2  1.27
18 months 1.89  1.41#* 7.12  1.36 SBP 136.7  16.5 132.0  17.8
DBP 80.6  11.3 82.9  12.5
24 months 2.16  1.57#* 7.25  1.29 SBP 133.1  12.6 129.6  119.9
DBP 78.79  12.7 76.6  12.4
30 months 2.00  1.66#* 7.60  1.62 SBP 133.9  12.6 130.5  19.9
DBP 76.4  12.7 77.2  12.5
36 months 1.99  1.43#* 7.41  1.51 SBP 135.1  17.7 136.8  19.7
DBP 79.7  11.3 76.1  12.6
Values are expressed as mean  SD. SBP, Systolic blood pressure; DBP, diastolic blood pressure.
a Patients who were treated with thyroid hormone for subclinical hypothyroidism.
b Patients who were not treated with thyroid hormone for subclinical hypothyroidism.
* P  0.001 vs. nontreated patients.
# P  0.001 vs. baseline.
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cardiac dysfunction in patients with subclinical hypothy-
roidism (15, 30), whether to treat subclinical hypothy-
roidism is still an issue of debate (31). In addition, the
impactof thyroidhormone therapyon the changes in renal
function inCKDpatientswith subclinical hypothyroidism
has never been explored. The results of the present study
showed that thyroid hormone replacement for subclinical
hypothyroidismpreserved renal function inCKDpatients.
Moreover, thyroid hormone treatmentwas found to be an
independent predictor of renal outcome in these patients.
Accumulating evidence has shown that subclinical hy-
pothyroidism is not a rare disorder in CKD patients. The
data of 14,623 adult participants from the third National
Health andNutritionExamination Survey (NHANES III),
a nationally representative sample of the United States
population, revealed that the prevalence of hypothyroid-
ism increased with reduced GFR, occurring in 10.9% of
patients with stage 2 CKD, 21.0%with stage 3 CKD, and
23.1% with stage 4 or 5 CKD, and that there was an
independently higher risk of hypothyroidism in stage 2–5
CKD patients even after adjusting for age, sex, and eth-
nicity (12). Among these hypothyroidism patients, 56%
were considered subclinical (12). Recently, Chonchol et
al. (14) showed that the prevalence of subclinical hypo-
thyroidism was 17.9% in patients with stage 3–5 CKD,
and that it was increased in persons with reduced eGFR
independent of age, sex, and fasting plasma glucose, total
cholesterol, and triglyceride concentrations. Moreover,
there was a graded increase in the likelihood of subclinical
hypothyroidism with progressively lower GFR and a sig-
nificant inverse association between eGFR andTSH levels
throughout the normal and high TSH ranges. Conversely,
a cross-sectional, population-based studyof29,480adults
without previously known thyroid disease demonstrated
that the prevalence of CKD was higher in people with
TSH in the middle and highest thirds of the reference
range and that CKD was more common in people with
subclinical hypothyroidism (32). Furthermore, TSH
within the normal range was also negatively associated
with eGFR (32). In the present study, we did not deter-
mine the prevalence of subclinical hypothyroidism in
CKD patients or the prevalence of CKD in patients with
subclinical hypothyroidism. However, although the
TSH concentrations of our subjects were above the nor-
mal range, a significant negative correlation was found
between eGFRandTSH levels, whichwas in accordance
with previous studies (32, 33).
FIG. 2. Kaplan-Meier plots for renal event-free survival in subclinical
hypothyroidism CKD patients with and without thyroid hormone
replacement therapy. Renal events were defined as halving of eGFR or
ESRD. The cumulative renal event-free renal survival was significantly
higher in patients treated with thyroid hormone.
TABLE 5. Multivariate Cox regression analysis for
renal outcome
Covariate HR (95% CI) P value
Age 1.01 (0.98–1.05) 0.47
Male (vs. female) 0.75 (0.33–1.71) 0.49
DM 2.71 (1.16–6.32) 0.02
Hormone replacement
therapy (vs. no treatment)
0.28 (0.12–0.68) 0.01
eGFR (ml/min/1.73 m2) 0.98 (0.96–1.00) 0.10
Serum cholesterol (mg/dl) 1.00 (0.99–1.01) 0.67
Serum triglyceride (mg/dl) 1.00 (1.00–1.01) 0.35
eGFR is calculated by MDRD-4 equation.
TABLE 4. Incidence of patients with 50% reduction in eGFR or ESRD according to thyroid hormone replacement
therapy
Treated patientsa Nontreated patientsb
Risk reduction with therapy,
% (95% CI)c
P
valuen (%)
Rate
(100 patient-yr) n (%)
Rate
(100 patient-yr)
Halving of eGFR 15 (8.3) 2.75 27 (20.9) 7.96 64 (0.19–0.67) 0.001
ESRD 2 (1.1) 0.37 8 (6.2) 2.36 85 (0.03–0.71) 0.006
eGFR is calculated by MDRD-4 equation.
a Patients who were treated with thyroid hormone for subclinical hypothyroidism.
b Patients who were not treated with thyroid hormone for subclinical hypothyroidism.
c The reduction in risk associated with thyroid hormone replacement therapy was calculated as (1  hazard ratio with thyroid hormone
treatment)  100.
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Thyroid hormone affects nearly all organ systems in the
body. In the kidney, it is involved in renal development and
growth, renal hemodynamics, and sodium and water ho-
meostasis (3).GFR is alsoknown tobe influencedby thyroid
dysfunction (2). Reduction in RPF and GFR, an increase in
serum creatinine concentration, and hyponatremia are fre-
quently observed in primary hypothyroidism patients (2, 3),
and these renal derangements are nearly normalized by thy-
roidhormone replacement therapy (17, 21). In addition, one
previous case study showed that a progressive deterioration
of renal function in a CKDpatient with severe hypothyroid-
ism was reversed by L-thyroxine (10). Moreover, thyroid
hormone treatment resulted in a rapid improvement of renal
function inhypothyroidpatientswith ischemicnephropathy
(18).However, these renal complications are not common
in patients with subclinical hypothyroidism. This may be
partly explained by the difference in plasma volume be-
tween overt hypothyroidism and subclinical hypothyroid-
ism patients. Plasma volume, RPF, and GFR were dem-
onstrated to be significantly decreased in patients with
overt primaryhypothyroidism,whereas therewasno clear
abnormality in blood volume in subclinical hypothyroid-
ism patients (21). Based on these findings, it was inferred
that the impactof thyroidhormone therapyon the changes
in eGFR in our patients was not a result of its effect on
plasma volume.
There are several theories as to why thyroid hormone
replacement preserved renal function in the subjects of the
present study. One possibility is that thyroid hormone
might improve cardiac dysfunction associated with sub-
clinical hypothyroidism. Prolonged isovolumic relaxation
time, lower early-late ratio ofDoppler-derived transmitral
peak flow velocities, reduced Doppler-derived mean aor-
tic acceleration, and impaired systolic function with ex-
ertion were observed even in subclinical hypothyroid pa-
tients (15, 34, 35). In addition, all these abnormalities
were normalized by L-thyroxine (30, 34). Therefore, the
consequence of thyroid hormone replacement therapy in
the present studymay be attributed to its beneficial effects
on cardiac function; however, this cannot be verified due
to the lack of baseline and follow-up echocardiography
results in our patients. Another possibility is that endo-
thelial dysfunction associated with subclinical hypothy-
roidismmaybe reversedby thyroidhormone replacement.
Lekakis et al. (36) found that TSH level was inversely
correlated with endothelium-dependent dilatation and
that flow-mediated dilatation (FMD), a marker of endo-
thelial function, was impaired in patients with subclinical
hypothyroidism as well as overt hypothyroidism. A study
by Cikim et al. (37) also demonstrated that FMD value
was significantly lower in the subclinical hypothyroid
grouprelative totheeuthyroidgroupwithoutanydifferences
in biochemical and metabolic parameters, suggesting that
subclinical hypothyroidism may have adverse effects on en-
dothelial function independent from other well-known ath-
erosclerotic risk factors. Lastly, thyroid hormone may im-
prove dyslipidemia in subclinical hypothyroidism patients.
Several previous studies have shown that serum total and
LDL-cholesterol concentrations were significantly higher in
patientswith subclinical hypothyroidism than in normal pa-
tients (8, 38). Moreover, restoration of euthyroidism by L-
thyroxine reduced both total and LDL-cholesterol levels,
which were more pronounced in patients with higher pre-
treatment serum cholesterol and TSH concentrations (16,
23). In the present study, we did not examine changes in the
levels of serum cholesterol or triglyceride. However, consid-
ering the baseline serum cholesterol and triglyceride concen-
trations and the results of multivariate Cox regression anal-
ysis, the effect of thyroid hormone replacement therapywas
presumed to be independent of dyslipidemia in the study
subjects. To explore the exact mechanism of renal function
preservation in subclinical hypothyroidism patients by thy-
roid hormone therapy, further additional studies with base-
line and follow-up echocardiography and/or FMD are
needed.
There has been controversy with regard to the man-
agement of subclinical hypothyroidism patients. Some
studies have found that L-thyroxine improves cardiac dys-
function and dyslipidemia and reduces symptoms of hy-
pothyroidism, including neuropsychiatric symptoms, in
patients with subclinical hypothyroidism (24–26, 39),
whereas others did not note any beneficial effects (27, 40).
We assume that the difference in the definition of subclin-
ical hypothyroidism and the heterogeneous age, sex, and
ethnicity of the study subjectsmay contribute to such con-
flicting findings. However, in general, accumulating evi-
dence indicates that subclinical hypothyroidism patients
with TSH level exceeding 10 IU/ml would benefit from
L-thyroxine therapy (6). For this reason, we excluded pa-
tients with extremely high TSH level in the final analysis
of the present study. Patients already on thyroid hormone
treatment were also excluded because the most common
cause of subclinical thyroid dysfunction was known to be
related to L-thyroxine therapy (6). On the other hand, it is
clearly recommended to carefully monitor the conse-
quences of thyroid hormone replacement due to a poten-
tial risk of overtreatment, resulting in a possibility of in-
ducing or exacerbating angina pectoris or cardiac
arrhythmia, especially in elderly patients (31). In our
study, therefore, fT4 and TSH concentrations were regu-
larly followed up every 3 months, and the dose of L-thy-
roxine was appropriately adjusted in all patients.
In the present study, serum cholesterol and triglyceride
levels at baselinewere significantly higher in the treatment
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group compared with the nontreatment group. In addi-
tion, not all patientsunderwent anti-TPOtesting, andhigh
titers of anti-TPO were observed only in the treatment
group. The evidence is insufficient to recommend either
for or against routine measurement of anti-TPO (41).
Moreover, previous studies have shown that subclinical
hypothyroidism patients with serum TSH level less than
10 mIU/liter are more likely to be treated when they have
positive anti-TPO (42). These can partly explainwhy only
45.3% of subjects in this study underwent anti-TPO test-
ing and why there was no patient with high titers of anti-
TPO in the nontreatment group. Furthermore, anti-TPO
was positive in only 18.8% (26 of 140) of our CKD pa-
tients with subclinical hypothyroidism, in whom the test
was performed.Theunderlyingmechanismsof subclinical
hypothyroidism besides autoimmunity in patients with
CKD are still unclear, but there have been some suggested
potential mechanisms linking CKD and subclinical hypo-
thyroidism. Serum iodine level can be elevated due to re-
duced renal clearance, resulting in prolongedWolff-Chai-
koff effect (12, 43). In addition, decreased peripheral
sensitivity to thyroid hormones, chronic metabolic acido-
sis, and the potential effects of retained solutes, such as
organic acids and guanidino compounds, has been in-
ferred to be associatedwith subclinical hypothyroidism in
patients with CKD (44–46). In the current study, how-
ever, the causes of subclinical hypothyroidism were not
investigated in detail. On the other hand, because the cur-
rent studywas a retrospectivemedical record-based study,
the differences in lipid profiles and autoimmunity are sup-
posed to be attributed to the lack of randomization of
patients, but the possibility of selection bias cannot be
completely ruled out. Despite this limitation, multivariate
Cox regression analysis revealed that thyroid hormone
replacementwas a significant independentpredictorof the
renal outcome. Therefore, we believe that this retrospec-
tive study provides useful information on the impact of
thyroid hormone replacement on the decline of eGFR in
CKD patients with subclinical hypothyroidism.
In conclusion, thyroid hormone therapy not only pre-
served renal function, but also was an independent pre-
dictor of renal outcome in CKD patients with subclinical
hypothyroidism, suggesting that thyroid hormone re-
placement should be considered in these patients.
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